Partners

Our partnerships are a cornerstone to our success. They provide expertise, knowledge, funding and in-kind support creating new collaborative opportunities for the CPDC.

The Networks of Centres of Excellence (NCE)

The NCE is a key partner of the CPDC, providing funding through its Centre’s of Excellence for Commercialization and Research Program. The NCE was created in 1989 as a joint initiative of the Natural Sciences and Engineering Research Council, the Social Sciences and Humanities Research Council, the Canadian Institutes of Health Research, Industry Canada and Health Canada. The NCE harnesses the best talent in the natural sciences, engineering, social sciences and health sciences, to build a more advanced, healthy, competitive and prosperous Canada. The centres and networks created through the NCE have steadily helped to form the right environment for industry and government to invest in Canadian innovations. In an average year, the Networks of Centres of Excellence leverages additional cash and in-kind contributions of almost $71 million from partners, creates eight spin-off companies, files over 100 patents and obtains close to 50 licenses. Since the inception of the NCE, over 100 companies have spun off from NCE-supported research.

The Ontario Institute for Cancer Research (OICR)

Through funding provided by our partner OICR, CPDC is able to develop in-house radiophamaceutical innovations, create intellectual property, and supply cutting edge agents to patients in Ontario. The OICR is an innovative cancer research and development institute dedicated to prevention, early detection, diagnosis and treatment of cancer. The Institute is an independent, not-for-profit corporation, funded by the Government of Ontario. OICR’s research supports more than 1,700 investigators, clinician scientists, research staff and trainees located at its headquarters and in research institutes and academia across the Province of Ontario. OICR has key research efforts underway in small molecules, biologics, stem cells, imaging, genomics, informatics and bio-computing.

McMaster University

McMaster University provides supporting infrastructure to the CPDC and has been our host institution since 2008. McMaster is one of the only 4 Canadian universities ranked among the top 100 in the world. McMaster has a long history in Nuclear Research stemming back more the 50 years since the opening of the McMaster Nuclear Reactor (MNR) in 1959. McMaster is recognized as a world-leader in radiation sciences, nuclear engineering, medical isotope and radiopharmaceutical production and research.

CanProbe

The Canadian Molecular Probe Consortium (CanProbe) is a not-for-profit joint venture created by CPDC and the University Health Network UHN).  Located in the heart of Toronto’s medical and discovery district, CanProbe operates a probe research, cyclotron, production and distribution centre serving UHN-affiliated and other Ontario hospitals with cutting edge radiopharmaceuticals for diagnosing and treating cancer and other serious diseases.

adMare Bioinnovations

CPDC and adMare BioInnovations launched a radiopharmaceutical initiative to support the translation of early-stage radiopharmaceuticals into the clinic called the CPDC and adMare Radiopharmaceutical Initiative (CARI). adMare BioInnovations is Canada’s Global Life Sciences Venture, building the Canadian life sciences industry from sea to sea. adMare’s specialized scientific and commercial expertise, as well as infrastructure together with CPDC’s radiopharmaceutical expertise as a leader in the radiopharmaceutical industry, provide essential support to CARI applicants to advance their commercially promising therapeutic innovations to the market.

CPDC executes its first commercial sublicensing agreement with Lawson Health Research Institute for PSMA-1007, expanding access to the prostate cancer diagnostic agent in Ontario

HAMILTON, ON, June 28, 2022 /CNW/ – The Centre for Probe Development and Commercialization (CPDC), a global leader in the development, production and commercialization of radiopharmaceuticals, has licensed [18F]PSMA-1007 from ABX- advanced biochemical compounds GmbH (Radeberg, Germany) and will hold the exclusive license to manufacture, commercialize and distribute the imaging agent in Canada. Concurrently, CPDC is also pleased to

CPDC’s Discovery Team is experienced in oncology, immuno-oncology, and neurology models.

CPDC and University Health Network have created a joint venture, CanProbe, to accelerate the clinical development of molecular imaging probes.

CPDC’s manufacturing facilities are approved by Health Canada for the production of positron emitting radiopharmaceuticals.

Global drug companies are using CPDC’s know-how and world-class facilities to develop and test new drugs and molecular probes.

During medical isotope shortages, CPDC can provide substitutes for use in bone scans and imaging kidney function.

CPDC can create PET and SPECT imaging companions for small molecules, peptides, antibodies and other biologics.

CPDC works with all therapeutic and diagnostic isotopes, and has extensive expertise with alpha and beta emitting nuclides.

Cyclotrons can be used to produce enough Tc-99m within 6 hours to enable over 500 nuclear imaging scans.

Molecular imaging probes can show a tumour’s biochemical response to treatment in just a few days, unlike conventional modes like MRI or CT, which may not show a change in tumour size for several weeks.

ARTMS Products Inc. has been created by Triumf, BCCA, LHRI and CPDC to commercialize jointly-developed technology for production of Tc-99m on standard medical cyclotrons.

Molecular PET imaging probes are used primarily to diagnose cancer, heart disease and neurological conditions.